GlySure develops continuous glucose monitoring (CGM) technology intended for in-hospital use to facilitate Tight Glycemic Control (TGC) in intensive care units. The company is led by CEO Chris Jones and Chairman Bill Moffitt. GlySure has raised $22.4M in venture capital to date. It completed a $13.6M second close of its Series C financing. The company intends to use the funding to complete clinical trials in support of U.S. and European regulatory clearance. Its products are not approved for use in the U.S. or Europe. GlySure develops a continuous intravascular glucose monitoring system that uses a proprietary optical fluorescence sensor for Tight Glycemic Control (TGC) in intensive care units. The company is Abingdon, UK–based and was founded in May 2006. It recently completed initial human use trials on over 90 intensive care patients. GlySure intends to use the new funding to complete clinical trials to support regulatory approval in the United States and Europe. The business has 16 employees. To date the company has raised $19.5M.

Total raised

$25M

Funding rounds

2

Latest round

Series C

Latest activity

Nov 2012